Stock FRX FENNEC PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Fennec Pharmaceuticals Inc. Toronto S.E.

Equities

FRX

CA31447P1009

Market Closed - Toronto S.E.
Other stock markets
 15:59:59 2024-07-17 EDT 		5-day change 1st Jan Change
9.1 CAD -0.55% Intraday chart for Fennec Pharmaceuticals Inc. +12.62% -39.97%
07-02 MT Newswires Weekend Stocks To Watch: BCE; Bitfarms; Fennec; GreenPower; Hut 8; Restaurant Brands; Sigma Lithium; Solaris MT
07-01 Fennec Pharmaceuticals Chief Operating Officer Adrian Haigh Steps Down MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's profit outlook over the next few years is a strong asset.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
FENNEC PHARMACEUTICALS INC. Stock Fennec Pharmaceuticals Inc.
-39.97% 182M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.03% 126B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+23.61% 117B
B+
ARGENX SE Stock argenx SE
+22.79% 27.52B
B
BIONTECH SE Stock BioNTech SE
-18.07% 20.87B
B+
GENMAB A/S Stock Genmab A/S
-14.41% 17.01B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.81% 16.26B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+9.78% 14.56B
C+
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.10% 15.09B
A-
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+52.34% 13.89B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. FENC Stock
  4. FRX Stock
  5. Ratings Fennec Pharmaceuticals Inc.